Proteogenomic biomarkers in colorectal cancers: clinical applications

References

• Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–691.
   PubMed Web of Science ®Google Scholar
• De Greef K, Rolfo C, Russo A, et al. Multidisciplinary management of patients with liver metastasis from colorectal cancer. World J Gastroenterol. 2016;22:7215–7225.
   PubMed Web of Science ®Google Scholar
• Duan L, Yang W, Wang X, et al. Advances in prognostic markers for colorectal cancer. Expert Rev Mol Diagn. 2019;19:313–324.
   PubMed Web of Science ®Google Scholar
• Issa IA, Noureddine M. Colorectal cancer screening: an updated review of the available options. World J Gastroenterol. 2017;23:5086–5096.
   PubMed Web of Science ®Google Scholar
• Chauvin A, Boisvert F-M. Clinical proteomics in colorectal cancer, a promising tool for improving personalised medicine. Proteomes. 2018;6:49.
   PubMed Web of Science ®Google Scholar
• Frago R, Ramirez E, Millan M, et al. Current management of acute malignant large bowel obstruction: a systematic review. Am J Surg. 2014;207:127–138.
   PubMed Web of Science ®Google Scholar
• Ogino S, Giannakis M. Immunoscore for (colorectal) cancer precision medicine. Lancet. 2018;391:2084–2086.
   PubMed Web of Science ®Google Scholar
• Cuyle P-J, Prenen H. Current and future biomarkers in the treatment of colorectal cancer. Acta Clin Belg. 2017;72:103–115.
   PubMed Web of Science ®Google Scholar
• Vasaikar S, Huang C, Wang X, et al. Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell. 2019;177:1035–1049.
   PubMed Web of Science ®Google Scholar
• Das V, Kalita J, Pal M. Predictive and prognostic biomarkers in colorectal cancer: a systematic review of recent advances and challenges. Biomed Pharmacother. 2017;87:8–19.
   PubMed Web of Science ®Google Scholar
• Menter DG, Davis JS, Broom BM, et al. Back to the colorectal cancer consensus molecular subtype future. Curr Gastroenterol Rep. 2019;21:5.
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646‐674.
   PubMed Web of Science ®Google Scholar
• Balacescu O, Sur D, Cainap C, et al. The impact of miRNA in colorectal cancer progression and its liver metastases. Int J Mol Sci. 2018;19:3711.
   Web of Science ®Google Scholar
• Gherman A, Balacescu L, Gheorghe-Cetean S, et al. Current and new predictors for treatment response in metastatic colorectal cancer. The role of circulating miRNAs as biomarkers. Int J Mol Sci. 2020;21:2089.
   Web of Science ®Google Scholar
• Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet Lond Engl. 2014;383:1490–1502.
   PubMed Web of Science ®Google Scholar
• Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–932.
   PubMed Web of Science ®Google Scholar
• Yang SY, Cho MS, Kim NK. Difference between right-sided and left-sided colorectal cancers: from embryology to molecular subtype. Expert Rev Anticancer Ther. 2018;18:351–358.
   PubMed Web of Science ®Google Scholar
• Natsume S, Yamaguchi T, Takao M, et al. Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients. Jpn J Clin Oncol. 2018;48:609–618.
   PubMed Web of Science ®Google Scholar
• The Lancet Oncology. Colorectal cancer: a disease of the young? Lancet Oncol. 2017;18:413.
   Web of Science ®Google Scholar
• Gupta N, Kupfer SS, Davis AM. Colorectal cancer screening. JAMA. 2019;321:2022–2023.
   PubMed Web of Science ®Google Scholar
• Nguyen MT, Weinberg DS. Biomarkers in colorectal cancer screening. J Natl Compr Canc Netw. 2016;14:1033–1040.
   PubMed Web of Science ®Google Scholar
• Weiser MR. AJCC 8th edition: colorectal cancer. Ann Surg Oncol. 2018;25:1454–1455.
   PubMed Web of Science ®Google Scholar
• Yan D, Yang X, Duan Y, et al. Comparison of laparoscopic complete mesocolic excision and traditional radical operation for colon cancer in the treatment of stage III colon cancer. J BUON Off J Balk Union Oncol. 2020;25:220–226.
   PubMed Web of Science ®Google Scholar
• Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet. 2019;394:1467–1480.
   PubMed Web of Science ®Google Scholar
• Rickard MJFX, Keshava A, Toh JWT. Three steps and a join: a simple guide to right- and left-sided medial to lateral laparoscopic colorectal surgery. Tech Coloproctol. 2017;21:673–677.
   PubMed Web of Science ®Google Scholar
• Ali SM, Pawlik TM, Rodriguez-Bigas MA, et al. Timing of surgical resection for curative colorectal cancer with liver metastasis. Ann Surg Oncol. 2018;25:32–37.
   PubMed Web of Science ®Google Scholar
• Ruan H, Leibowitz BJ, Zhang L, et al. Immunogenic cell death in colon cancer prevention and therapy. Mol Carcinog. 2020 Mar 25;59:783–793. [published ahead of print].
   PubMed Web of Science ®Google Scholar
• Yang X, Liu M, Li M, et al. Epigenetic modulations of noncoding RNA: a novel dimension of cancer biology. Mol Cancer. 2020;19:64.
   PubMed Web of Science ®Google Scholar
• Yu IS, Cheung WY. Metastatic colorectal cancer in the era of personalized medicine: a more tailored approach to systemic therapy. Can J Gastroenterol Hepatol. 2018;2018:9450754.
   PubMed Web of Science ®Google Scholar
• Surinova S, Choi M, Tao S, et al. Prediction of colorectal cancer diagnosis based on circulating plasma proteins. EMBO Mol Med. 2015;7:1166–1178.
   PubMed Web of Science ®Google Scholar
• Chen J, Sun H, Tang W, et al. DNA methylation biomarkers in stool for early screening of colorectal cancer. J Cancer. 2019;10:5264–5271.
   PubMed Web of Science ®Google Scholar
• Surinova S, Radová L, Choi M, et al. Non-invasive prognostic protein biomarker signatures associated with colorectal cancer. EMBO Mol Med. 2015;7:1153–1165.
   PubMed Web of Science ®Google Scholar
• De’ Angelis GL, Bottarelli L, Azzoni C, et al. Microsatellite instability in colorectal cancer. Acta Bio Medica Atenei Parm. 2018;89:97–101.
   PubMedGoogle Scholar
• Voorneveld PW, Jacobs RJ, Kodach LL, et al. A meta-analysis of SMAD4 immunohistochemistry as a prognostic marker in colorectal cancer. Transl Oncol. 2015;8:18–24.
   PubMed Web of Science ®Google Scholar
• Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the «RASCAL II» study. Br J Cancer. 2001;85:692–696.
   PubMed Web of Science ®Google Scholar
• Tong G, Xu W, Zhang G, et al. The role of tissue and serum carcinoembryonic antigen in stages I to III of colorectal cancer – a retrospective cohort study. Cancer Med. 2018;7:5327–5338.
   PubMed Web of Science ®Google Scholar
• Okamura R, Hasegawa S, Hida K, et al. The role of periodic serum CA19-9 test in surveillance after colorectal cancer surgery. Int J Clin Oncol. 2017;22:96–101.
   PubMed Web of Science ®Google Scholar
• van der Waals LM, Laoukili J, Jongen JMJ, et al. Differential anti-tumour effects of MTH1 inhibitors in patient-derived 3D colorectal cancer cultures. Sci Rep. 2019;9:819.
   PubMed Web of Science ®Google Scholar
• Safaie Qamsari E, Safaei Ghaderi S, Zarei B, et al. The c-Met receptor: implication for targeted therapies in colorectal cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2017;39:1010428317699118.
   Google Scholar
• Li X-L, Zhou J, Chen Z-R, et al. P53 mutations in colorectal cancer – molecular pathogenesis and pharmacological reactivation. World J Gastroenterol. 2015;21:84–93.
   PubMed Web of Science ®Google Scholar
• Vedeld HM, Nesbakken A, Lothe RA, et al. Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer. Clin Epigenetics. 2018;10:70.
   PubMed Web of Science ®Google Scholar
• Kuan T-C, Lin P-C, Yang S-H, et al. Impact of LINE-1 hypomethylation on the clinicopathological and molecular features of colorectal cancer patients. PloS One. 2018;13:e0197681.
   PubMed Web of Science ®Google Scholar
• Lech G, Słotwiński R, Słodkowski M, et al. Colorectal cancer tumour markers and biomarkers: recent therapeutic advances. World J Gastroenterol. 2016;22:1745–1755.
   PubMed Web of Science ®Google Scholar
• Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6:140–146.
   PubMed Web of Science ®Google Scholar
• Ten Hoorn S, Trinh A, de Jong J, et al. Classification of colorectal cancer in molecular subtypes by immunohistochemistry. Methods Mol Biol. 2018;1765:179–191.
   PubMedGoogle Scholar
• Linnekamp JF, van Hooff SR, Prasetyanti PR, et al. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. Cell Death Differ. 2018;25:616–633.
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA, Bossuyt PMM. Waste, leaks, and failures in the biomarker pipeline. Clin Chem. 2017;63:963–972.
   PubMed Web of Science ®Google Scholar
• Valle L, de Voer RM, Goldberg Y, et al. Update on genetic predisposition to colorectal cancer and polyposis. Mol Aspects Med. 2019;69:10–26.
   PubMed Web of Science ®Google Scholar
• Afkhami E, Heidari MM, Khatami M, et al. Detection of novel mitochondrial mutations in cytochrome C oxidase subunit 1 (COX1) in patients with familial adenomatous polyposis (FAP). Clin Transl Oncol. 2020;22:908–918.
   PubMed Web of Science ®Google Scholar
• Sinicrope FA. Lynch syndrome–associated colorectal cancer. N Engl J Med. 2018;379:764–773.
   PubMed Web of Science ®Google Scholar
• Jiang Y-L, Zhao Z-Y, Li B-R, et al. The altered activity of P53 signaling pathway by STK11 gene mutations and its cancer phenotype in Peutz-Jeghers syndrome. BMC Med Genet. 2018;19:141.
   PubMed Web of Science ®Google Scholar
• Ma H, Brosens LAA, Offerhaus GJA, et al. Pathology and genetics of hereditary colorectal cancer. Pathology. 2018;50:49–59.
   PubMed Web of Science ®Google Scholar
• Maida M, Morreale G, Sinagra E, et al. Quality measures improving endoscopic screening of colorectal cancer: a review of the literature. Expert Rev Anticancer Ther. 2019;19:223–235.
   PubMed Web of Science ®Google Scholar
• Castro G, Azrak MF, Seeff LC, et al. Outpatient colonoscopy complications in the CDC’s colorectal cancer screening demonstration program. Cancer. 2013;119:2849–2854.
   PubMed Web of Science ®Google Scholar
• Sun M, Liu J, Hu H, et al. A novel panel of stool-based DNA biomarkers for early screening of colorectal neoplasms in a Chinese population. J Cancer Res Clin Oncol. 2019;145:2423–2432.
   PubMed Web of Science ®Google Scholar
• Wang W, Xu X, Tian B, et al. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Clin Chim Acta. 2017;470:51–55.
   PubMed Web of Science ®Google Scholar
• Gao Y, Wang J, Zhou Y, et al. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. Sci Rep. 2018;8:2732.
   PubMed Web of Science ®Google Scholar
• Bustamante-Lopez LA, Nahas SC, Nahas CSR, et al. Is there a difference between right versus left-sided colon cancers? Does side make any difference in long-term follow-up? Arq Bras Cir Dig. 2019;32:e1479.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Sugai T, Habano W, et al. Molecular differences in the microsatellite stable phenotype between left-sided and right-sided colorectal cancer. Int J Cancer. 2016;139:2493–2501.
   PubMed Web of Science ®Google Scholar
• Alves Martins BA, de Bulhões GF, Cavalcanti IN, et al. Biomarkers in colorectal cancer: the role of translational proteomics research. Front Oncol. 2019;9:1284.
   PubMed Web of Science ®Google Scholar
• Salem ME, Puccini A, Tie J. Redefining colorectal cancer by tumor biology. Am Soc Clin Oncol Educ Book. 2020;40:1–13.
   PubMedGoogle Scholar
• Akkad J, Bochum S, Martens UM. Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies. Langenbecks Arch Surg. 2015;400:129–143.
   PubMed Web of Science ®Google Scholar
• Iorio J, Lastraioli E, Tofani L, et al. hERG1 and HIF-2α behave as biomarkers of positive response to bevacizumab in metastatic colorectal cancer patients. Transl Oncol. 2020;13:100740.
   PubMed Web of Science ®Google Scholar
• Ren D, Lin B, Zhang X, et al. Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway. Oncotarget. 2017;8:49807–49823.
   PubMed Web of Science ®Google Scholar
• Fujio A, Usuda M, Ozawa Y, et al. A case of gastrointestinal bleeding due to right hepatic artery pseudoaneurysm following total remnant pancreatectomy: a case report. Int J Surg Case Rep. 2017;41:434–437.
   PubMed Web of Science ®Google Scholar
• Qin Y, Li L, Wang F, et al. Knockdown of Mir-135b sensitizes colorectal cancer cells to oxaliplatin-induced apoptosis through increase of FOXO1. Cell Physiol Biochem. 2018;48:1628–1637.
   PubMedGoogle Scholar
• Qian X, Yu J, Yin Y, et al. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle Georget Tex. 2013;12:1385–1394.
   PubMed Web of Science ®Google Scholar
• Wang K-Y, Ma J, Zhang F-X, et al. MicroRNA-378 inhibits cell growth and enhances L-OHPinduced apoptosis in human colorectal cancer. IUBMB Life. 2014;66:645–654.
   PubMed Web of Science ®Google Scholar
• Liu C, Eng C, Shen J, et al. Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. Oncotarget. 2016;7:76250–76260.
   PubMedGoogle Scholar
• Li LS, Morales JC, Veigl M, et al. DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. Br J Pharmacol. 2009;158:679–692.
   PubMed Web of Science ®Google Scholar
• Caso R, Fabrizio A, Sosin M. Prolonged follow-up of colorectal cancer patients after 5 years: to follow or not to follow, that is the question (and how)! Ann Transl Med. 2020;8:164.
   PubMed Web of Science ®Google Scholar
• Boeckx N, Op de Beeck K, Beyens M, et al. Mutation and methylation analysis of circulating tumor DNA can be used for follow-up of metastatic colorectal cancer patients. Clin Colorectal Cancer. 2018;17:369–379.
   PubMed Web of Science ®Google Scholar
• Ramphal W, Boeding JRE, van Iwaarden M, et al. Serum carcinoembryonic antigen to predict recurrence in the follow-up of patients with colorectal cancer. Int J Biol Markers. 2019;34:60–68.
   PubMed Web of Science ®Google Scholar
• Barault L, Amatu A, Siravegna G, et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut. 2018;67:1995–2005.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhao L, Zhou P, et al. Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy. Cancer Cell Int. 2017;17:6.
   PubMed Web of Science ®Google Scholar
• Koncina E, Haan S, Rauh S, et al. Prognostic and predictive molecular biomarkers for colorectal cancer: updates and challenges. Cancers (Basel). 2020;12:319.
   PubMed Web of Science ®Google Scholar
• de Cuba EMV, Snaebjornsson P, Heideman DA, et al. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers. Int J Cancer. 2016;138:1139–1145.
   PubMed Web of Science ®Google Scholar
• Lee J-H, Ahn J, Park WS, et al. Colorectal cancer prognosis is not associated with BRAF and KRAS mutations – a STROBE compliant study. J Clin Med. 2019;8(1):pii: E111.
   Web of Science ®Google Scholar
• Zhao M, Mishra L, Deng C-X. The role of TGF-β/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14:111–123.
   PubMed Web of Science ®Google Scholar
• Vedeld HM, Merok M, Jeanmougin M, et al. CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers. Int J Cancer. 2017;141:967–976.
   PubMed Web of Science ®Google Scholar
• Jimenez CR, Knol JC, Meijer GA, et al. Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J Proteomics. 2010;73:1873–1895.
   PubMed Web of Science ®Google Scholar
• Chen X, Sun J, Wang X, et al. A meta-analysis of proteomic blood markers of colorectal cancer. Curr Med Chem. 2020 Apr 26 [published ahead of print]. doi:10.2174/0929867327666200427094054.
   Web of Science ®Google Scholar
• Ma YS, Huang T, Zhong XM, et al. Proteogenomic characterization and comprehensive integrative genomic analysis of human colorectal cancer liver metastasis. Mol Cancer. 2018;17:139.
   PubMed Web of Science ®Google Scholar
• Blank-Landeshammer B, Richard VR, Mitsa G, et al. Proteogenomics of colorectal cancer liver metastases: complementing precision oncology with phenotypic data. Cancers (Basel). 2019;11(12):pii: E1907.
   PubMed Web of Science ®Google Scholar
• Imperial R, Ahmed Z, Toor OM, et al. Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles. Mol Cancer. 2018;17:177.
   PubMed Web of Science ®Google Scholar